Overview

CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory AML or MDS

Status:
Unknown status
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
A Phase I Combination Study of CYC065 and Venetoclax for Relapsed or Refractory AML or MDS
Phase:
Phase 1
Details
Lead Sponsor:
Cyclacel Pharmaceuticals, Inc.
Collaborator:
M.D. Anderson Cancer Center
Treatments:
Adenosine
Venetoclax